TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07263685: Retrospective Chart Review Study Evaluating Clinical Effectiveness and Impact on Quality of Life Among Patients Who Initiated Long-term Prophylaxis With Takhzyro® in a Real-World Setting in the Kingdom of Saudi Arabia - the REFLEQT-KSA Study (Retrospective Evaluation Focusing on Lanadelumab's Effectiveness and Impact on Quality of Life in The Kingdom of Saudi Arabia)

Sponsor: Takeda · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 50 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT07263685 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07263685 Rescue Dossier →